3-Acetylpyridine NAD
(Synonyms: 3-乙酰吡啶腺嘌呤二核苷酸,APAD, NSC 20275) 目录号 : GC18294A NAD analog
Cas No.:86-08-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
3-Acetylpyridine NAD (APAD) is an analog of NAD+ (free acid) , a signaling molecule and cofactor or substrate for many enzymes. APAD has been used to study the mechanisms of oxidative phosphorylation. It can be reduced by transdehydrogenase from NADH (sodium salt) . It can be reduced more efficiently and is more stable than NAD+; thus, it is useful as a substitute.
References:
[1]. Houtkooper, R.H., Cantó, C., Wanders, R.J., et al. The secret life of NAD+: An old metabolite controlling new metabolic signaling pathways Endocr. Rev. 31(2), 194-223 (2010).
[2]. Ciaccio, E.I. The inhibition of lactate dehydrogenase by 3-acetylpyridine adenine dinucleotide and bisulfite J. Biol. Chem. 241(7), 1581-1586 (1966).
[3]. Birrell, J.A., and Hirst, J. Investigation of NADH binding, hydride transfer, and NAD(+) dissociation during NADH oxidation by mitochondrial complex I using modified nicotinamide nucleotides Biochemistry 52(23), 4048-4055 (2013).
[4]. Stilwell, S.N., Bizouam, T., and Jackson, J.B. The reduction of acetylpyridine adenine dinucleotide by NADH: is it a significant reaction of proton-translocating transhydrogenase, or an artefact? Biochim Biophys. Acta. 1320(1), 83-94 (1997).
[5]. Lee, H.J., Lee, S.H., Park, C.B., et al. Coenzyme analogs: Excellent substitutes (not poor imitations) for electrochemical regeneration Chem. Commun. (Camb.) 47(46), 12538-12540 (2011).
| Cas No. | 86-08-8 | SDF | |
| 别名 | 3-乙酰吡啶腺嘌呤二核苷酸,APAD, NSC 20275 | ||
| 化学名 | adenosine 5'-(trihydrogen diphosphate), P’→5’-ester with 3-acetyl-1-β-D-ribofuranosylpyridinium, inner salt | ||
| Canonical SMILES | O[C@H]1[C@H](N2C=NC3=C2N=CN=C3N)O[C@H](COP(OP(OC[C@@H]4[C@@H](O)[C@@H](O)[C@H]([N+]5=CC(C(C)=O)=CC=C5)O4)([O-])=O)(O)=O)[C@H]1O | ||
| 分子式 | C22H28N6O14P2 | 分子量 | 662.4 |
| 溶解度 | 10mg/ml in PBS (pH 7.2) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.5097 mL | 7.5483 mL | 15.0966 mL |
| 5 mM | 0.3019 mL | 1.5097 mL | 3.0193 mL |
| 10 mM | 0.151 mL | 0.7548 mL | 1.5097 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。